Hospital Volume, Quality Impact Survival in Ovarian Cancer

Share this content:
Hospital Volume, Quality Impact Survival in Ovarian Cancer
Hospital Volume, Quality Impact Survival in Ovarian Cancer

FRIDAY, Aug. 11, 2017 (HealthDay News) -- For patients with ovarian cancer, both hospital volume and adherence to quality metrics are associated with survival, according to a study published in the September issue of Obstetrics & Gynecology.

Jason D. Wright, M.D., from the Columbia University College of Physicians and Surgeons in New York City, and colleagues used the National Cancer Database to perform a retrospective study of women with ovarian cancer. Survival rates were compared based on annual case volume and adherence to ovarian cancer quality metrics.

The researchers identified 100,725 patients at 1,268 hospitals. The likelihood of adhering to quality metrics was increased for higher volume hospitals. There was an increase in both two- and five-year survival with hospital volume and with adherence to the measured quality metrics; two-year survival increased from 64.4 to 77.4 percent at low- and high-volume centers, respectively, and from 66.5 to 77.3 percent at low- and high-quality hospitals, respectively (both P < 0.001). Survival increased with increasing adherence to quality metrics for each hospital volume category. Survival was still lower at lower volume hospitals with higher quality scores versus higher volume hospitals.

"Although both hospital volume and adherence to quality metrics are associated with survival for ovarian cancer, low-volume hospitals that provide high-quality care still have survival rates that are lower than high-volume centers," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths